Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Nyanhete TE, Frisbee AL, Bradley T, Faison WJ, Robins E, Payne T, Freel SA, Sawant S, Weinhold KJ, Wiehe K, Haynes BF, Ferrari G, Li QJ, Moody MA, Tomaras GD.

Sci Rep. 2019 Jul 15;9(1):10165. doi: 10.1038/s41598-019-46462-8.

2.

Flow Cytometry Characterization of Cerebrospinal Fluid Monocytes in Patients With Postoperative Cognitive Dysfunction: A Pilot Study.

Berger M, Murdoch DM, Staats JS, Chan C, Thomas JP, Garrigues GE, Browndyke JN, Cooter M, Quinones QJ, Mathew JP, Weinhold KJ, Amundsen CL, Bengali S, Brigman BE, Bullock WM, Carter J, Chapman J, Cheong Yee Ching V, Cohen HJ, Colin B, D'Amico TA, Devinney MJ, DeOrio JK, Ellet T, Esclamado RM, Ferrandino MN, Gadsden J, Guercio J, Habib A, Harpole DH, Hartwig MG, Iboaya E, Inman BA, Khan A, Lagoo-Deenadayalan S, Lee PS, Lee WT, Lemm J, Levinson H, Mantyh C, McDonagh DL, Migaly J, Mithani SK, Moretti E, Moul JW, Newman MF, Ni K, Ohlendorf B, Perez A, Peterson AC, Ponussamy V, Preminger GM, Robertson CN, Roman SA, Runyon S, Sandler A, Scheri RP, Smith SK, Talbot L, Thacker JKM, Tong BC, Tu A, Vaslef SN, Waldron N, Wang X, Whitson H, Wickenheisser V, Young C; MADCO-PC Study Team; Markers of Alzheimer’s Disease and neuroCognitive Outcomes after Perioperative Care (MADCO-PC).

Anesth Analg. 2019 Nov;129(5):e150-e154. doi: 10.1213/ANE.0000000000004179.

PMID:
31085945
3.

The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction.

Berger M, Oyeyemi D, Olurinde MO, Whitson HE, Weinhold KJ, Woldorff MG, Lipsitz LA, Moretti E, Giattino CM, Roberts KC, Zhou J, Bunning T, Ferrandino M, Scheri RP, Cooter M, Chan C, Cabeza R, Browndyke JN, Murdoch DM, Devinney MJ, Shaw LM, Cohen HJ, Mathew JP; INTUIT Investigators.

J Am Geriatr Soc. 2019 Apr;67(4):794-798. doi: 10.1111/jgs.15770. Epub 2019 Jan 23.

PMID:
30674067
4.

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, Stempora L, Hammond C, Wouters A, Mojcik CF, Cheng J, Collinge M, Jesson MI, Hazra A, Biswas P, Lan S, Clark JD, Hodge JA.

Clin Immunol. 2018 Jun;191:10-20. doi: 10.1016/j.clim.2018.03.002. Epub 2018 Mar 5.

5.

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE.

Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.

6.

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.

7.

Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.

Yi JS, Ready N, Healy P, Dumbauld C, Osborne R, Berry M, Shoemaker D, Clarke J, Crawford J, Tong B, Harpole D, D'Amico TA, McSherry F, Dunphy F, McCall SJ, Christensen JD, Wang X, Weinhold KJ.

Clin Cancer Res. 2017 Dec 15;23(24):7474-7482. doi: 10.1158/1078-0432.CCR-17-2005. Epub 2017 Sep 26.

8.

B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity.

Yi JS, Russo MA, Massey JM, Juel V, Hobson-Webb LD, Gable K, Raja SM, Balderson K, Weinhold KJ, Guptill JT.

Front Neurol. 2017 Feb 10;8:34. doi: 10.3389/fneur.2017.00034. eCollection 2017.

9.

Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes.

Zidar DA, Mudd JC, Juchnowski S, Lopes JP, Sparks S, Park SS, Ishikawa M, Osborne R, Washam JB, Chan C, Funderburg NT, Owoyele A, Alaiti MA, Mayuga M, Orringer C, Costa MA, Simon DI, Tatsuoka C, Califf RM, Newby LK, Lederman MM, Weinhold KJ.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):389-97. doi: 10.1161/ATVBAHA.115.306112. Epub 2015 Dec 10.

10.

Adaptive immune response to therapy in hmgcr autoantibody myopathy.

Yi JS, Russo MA, Weinhold KJ, Guptill JT.

Muscle Nerve. 2016 Feb;53(2):313-7. doi: 10.1002/mus.24947. Epub 2015 Dec 29.

11.

Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation.

Snyder LD, Chan C, Kwon D, Yi JS, Martissa JA, Copeland CA, Osborne RJ, Sparks SD, Palmer SM, Weinhold KJ.

Am J Respir Crit Care Med. 2016 Jan 1;193(1):78-85. doi: 10.1164/rccm.201504-0733OC.

12.

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr.

13.

Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis.

Foster MW, Morrison LD, Todd JL, Snyder LD, Thompson JW, Soderblom EJ, Plonk K, Weinhold KJ, Townsend R, Minnich A, Moseley MA.

J Proteome Res. 2015 Feb 6;14(2):1238-49. doi: 10.1021/pr501149m. Epub 2015 Jan 14.

PMID:
25541672
14.

Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays.

Staats JS, Enzor JH, Sanchez AM, Rountree W, Chan C, Jaimes M, Chan RC, Gaur A, Denny TN, Weinhold KJ.

J Immunol Methods. 2014 Jul;409:44-53. doi: 10.1016/j.jim.2014.05.021. Epub 2014 Jun 23.

15.

High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes.

Nair SK, Tomaras GD, Sales AP, Boczkowski D, Chan C, Plonk K, Cai Y, Dannull J, Kepler TB, Pruitt SK, Weinhold KJ.

Sci Rep. 2014 Apr 23;4:4632. doi: 10.1038/srep04632.

16.

Setting objective thresholds for rare event detection in flow cytometry.

Richards AJ, Staats J, Enzor J, McKinnon K, Frelinger J, Denny TN, Weinhold KJ, Chan C.

J Immunol Methods. 2014 Jul;409:54-61. doi: 10.1016/j.jim.2014.04.002. Epub 2014 Apr 12.

17.

Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Yi JS, Guidon A, Sparks S, Osborne R, Juel VC, Massey JM, Sanders DB, Weinhold KJ, Guptill JT.

J Autoimmun. 2014 Aug;52:130-8. doi: 10.1016/j.jaut.2013.12.005. Epub 2013 Dec 28.

18.

Managing Multi-center Flow Cytometry Data for Immune Monitoring.

White S, Laske K, Welters MJ, Bidmon N, van der Burg SH, Britten CM, Enzor J, Staats J, Weinhold KJ, Gouttefangeas C, Chan C.

Cancer Inform. 2015 Jun 10;13(Suppl 7):111-22. doi: 10.4137/CIN.S16346. eCollection 2014.

19.

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.

Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT.

Muscle Nerve. 2013 Dec;48(6):992-3. doi: 10.1002/mus.24063. Epub 2013 Oct 7. No abstract available.

20.

Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.

Shetty G, Beasley GM, Sparks S, Barfield M, Masoud M, Mosca PJ, Pruitt SK, Salama AK, Chan C, Tyler DS, Weinhold KJ.

Ann Surg Oncol. 2013 Apr;20(4):1128-35. doi: 10.1245/s10434-012-2785-5. Epub 2013 Mar 2.

21.

Upregulation of IL-1β, IL-6, and CCL-2 by a novel mouse model of pancreatic ischemia-reperfusion injury.

Lunsford KE, Baird BJ, Sempowski GD, Cardona DM, Li Z, Weinhold KJ, Sudan DL, Brennan TV.

Transplantation. 2013 Apr 27;95(8):1000-7. doi: 10.1097/TP.0b013e318286483a.

22.

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.

Yates NL, Stacey AR, Nolen TL, Vandergrift NA, Moody MA, Montefiori DC, Weinhold KJ, Blattner WA, Borrow P, Shattock R, Cohen MS, Haynes BF, Tomaras GD.

Mucosal Immunol. 2013 Jul;6(4):692-703. doi: 10.1038/mi.2012.107. Epub 2013 Jan 9.

23.

Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.

Gabitzsch ES, Balint-Junior JP, Xu Y, Balcaitis S, Sanders-Beer B, Karl J, Weinhold KJ, Paessler S, Jones FR.

Vaccine. 2012 Nov 26;30(50):7265-70. doi: 10.1016/j.vaccine.2012.09.058. Epub 2012 Oct 2.

24.

Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, Kirchherr JL, Soderberg KA, Weinhold KJ, Cunningham CK, Denny TN, Crump JA, Cohen MS, McMichael AJ, Haynes BF, Tomaras GD.

J Virol. 2012 Jun;86(12):6835-46. doi: 10.1128/JVI.00437-12. Epub 2012 Apr 18.

25.

OMIP-006: phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry.

Murdoch DM, Staats JS, Weinhold KJ.

Cytometry A. 2012 Apr;81(4):281-3. doi: 10.1002/cyto.a.22024. Epub 2012 Feb 8.

26.

Empowering diabetic children. Camp Red Jacket makes a difference.

Weinhold KJ.

Healthc Exec. 2011 Sep-Oct;26(5):66, 68. No abstract available.

PMID:
21932622
27.

High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, Komoriya A, Ochsenbauer C, Kappes JC, Roederer M, Huang Y, Weinhold KJ, Tomaras GD, Haynes BF, Montefiori DC, Ferrari G.

Cytometry A. 2011 Aug;79(8):603-12. doi: 10.1002/cyto.a.21084. Epub 2011 Jul 6.

28.

Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection.

Ferrari G, Korber B, Goonetilleke N, Liu MK, Turnbull EL, Salazar-Gonzalez JF, Hawkins N, Self S, Watson S, Betts MR, Gay C, McGhee K, Pellegrino P, Williams I, Tomaras GD, Haynes BF, Gray CM, Borrow P, Roederer M, McMichael AJ, Weinhold KJ.

PLoS Pathog. 2011 Feb 10;7(2):e1001273. doi: 10.1371/journal.ppat.1001273.

29.

Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.

Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, Weinhold KJ.

Am J Transplant. 2011 Mar;11(3):553-60. doi: 10.1111/j.1600-6143.2010.03405.x. Epub 2011 Jan 10.

30.

Optimization of a highly standardized carboxyfluorescein succinimidyl ester flow cytometry panel and gating strategy design using discriminative information measure evaluation.

Chan C, Lin L, Frelinger J, Hérbert V, Gagnon D, Landry C, Sékaly RP, Enzor J, Staats J, Weinhold KJ, Jaimes M, West M.

Cytometry A. 2010 Dec;77(12):1126-36. doi: 10.1002/cyto.a.20987.

31.

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF; AIDS Vaccine Evaluation Group.

PLoS One. 2010 Aug 10;5(8):e11995. doi: 10.1371/journal.pone.0011995.

32.

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.

Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD.

J Virol. 2010 May;84(10):4998-5006. doi: 10.1128/JVI.00138-10. Epub 2010 Mar 3.

33.

Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS).

Murdoch DM, Suchard MS, Venter WD, Mhlangu P, Ottinger JS, Feldman C, Van Rie A, Glencross DK, Stevens WS, Weinhold KJ.

AIDS Res Ther. 2009 Jul 16;6:16. doi: 10.1186/1742-6405-6-16.

34.

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.

Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S; CHAVI Clinical Core B, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ.

J Exp Med. 2009 Jun 8;206(6):1253-72. doi: 10.1084/jem.20090365. Epub 2009 Jun 1.

35.

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.

36.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2009 Jan 7;27(2):243-9. doi: 10.1016/j.vaccine.2008.10.051. Epub 2008 Nov 7.

37.

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF.

J Virol. 2008 Dec;82(24):12449-63. doi: 10.1128/JVI.01708-08. Epub 2008 Oct 8.

38.

Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.

Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, Reich CF 3rd, Qin L, Self SG, Shaw GM, Denny TN, Jones LE, Pisetsky DS, Haynes BF.

J Virol. 2008 Aug;82(15):7700-10. doi: 10.1128/JVI.00605-08. Epub 2008 May 28.

39.

Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.

Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND; HIV Vaccine Trials Network.

Vaccine. 2008 Jan 10;26(2):215-23. Epub 2007 Nov 20.

PMID:
18055072
40.

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF.

J Virol. 2008 Jan;82(1):115-25. Epub 2007 Oct 17.

41.

Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.

Robinson HL, Weinhold KJ.

J Infect Dis. 2006 Dec 15;194(12):1625-7. Epub 2006 Nov 8. No abstract available.

PMID:
17109331
42.

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12.

43.

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.

Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL; NIH/NIAID/DAIDS HIV Vaccine Trials Network.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):678-83.

PMID:
16831092
44.

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.

Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM, Ambrozak DR, Tomaras G, Roederer M, Kilby JM, Tartaglia J, Belshe R, Gao F, Douek DC, Weinhold KJ, Koup RA, Goepfert P, Ferrari G.

Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4512-7. Epub 2005 Mar 7.

45.

Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.

Kaplan SS, Ferrari G, Wrin T, Hellmann NS, Tomaras GD, Gryszowka VE, Fiscus SA, Weinhold KJ, Hicks CB.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):13-6.

PMID:
15665640
46.

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network.

J Infect Dis. 2004 Dec 1;190(11):1962-9. Epub 2004 Oct 28.

PMID:
15529261
47.

Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.

Ferrari G, Neal W, Ottinger J, Jones AM, Edwards BH, Goepfert P, Betts MR, Koup RA, Buchbinder S, McElrath MJ, Tartaglia J, Weinhold KJ.

J Immunol. 2004 Aug 1;173(3):2126-33.

48.

HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians.

Ferrari G, Currier JR, Harris ME, Finkelstein S, de Oliveira A, Barkhan D, Cox JH, Zeira M, Weinhold KJ, Reinsmoen N, McCutchan F, Birx DL, Osmanov S, Maayan S.

Hum Immunol. 2004 Jun;65(6):648-59.

PMID:
15219385
49.

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

J Infect Dis. 2004 Apr 1;189(7):1221-31. Epub 2004 Mar 15.

PMID:
15031791
50.

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.

Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, Staats HF, Patel DD, Sempowski GD, Hellmann NS, Weinhold KJ, Hicks CB.

J Infect Dis. 2003 Apr 1;187(7):1027-37. Epub 2003 Mar 13.

PMID:
12660916

Supplemental Content

Loading ...
Support Center